Gritstone Oncology, which focuses on personalized cancer immunotherapy, opened a new biomanufacturing facility in Pleasanton, CA, to produce the company’s first investigational products.
In this week's FiercePharmaAsia wrap-up, Takeda and VC Lightstone have joined forces in forming a neuroscience startup, China's cancer research is narrowing the U.S. lead, Sun's Halol plant was hit by FDA notice again, and more.
Though cancer vaccines have experienced disappointing clinical performance in recent years, their global market as a crucial tool in immunotherapy will grow to $7.5 billion by 2022, a new report predicts.
